Genaera Corp

Genaera — BIO Investor Forum 2008

17 slides from Genaera's conference presentation, Oct 31, 2008

  1. Slide 1: BIO Investor Forum

    Exhibit 99.1 BIO Investor Forum October 2008

  2. Slide 2: Business Overview

    Business Overview • Two core assets with significant upside in expanding markets – Type 2 Diabetes – Obesity – Respiratory • Focused library of back-up compounds • Focused clinical programs • Significant unrecognized value for core assets

  3. Slide 3: Product Overview

    Product Overview MEDI-528 (Anti-IL9 Antibody) • Phase 2 development for atopic and non-atopic asthma • Licensed to MedImmune in 2001 – > $50M in remaining milestones (post-2010) – Start of Phase 3 and BLA filing = ~$4M (total) • No development costs to Genaera; IP support • Acceptable adverse event

  4. Slide 4: MSI-1436 Differentiation

    MSI-1436 Differentiation • Competitively positioned to treat both type 2 diabetes and obesity with one drug – Primary impact on insulin sensitization and appetite suppression – Over time may impact factors of fatty-liver disease (NASH) • Mechanism of Action = PTP-1B Inhibition – Inhibits PTP-1B both

  5. Slide 5: Clinical Summary

    Clinical Summary Study MSI-1436C-102: Phase 1b – Ascending multiple dose study in obese/overweight type 2 diabetic subjects • Not well controlled on metformin – 3 cohorts of dosing intervals • Every 3 days, 8 total doses – Primary outcomes: Safety and multiple dose PK – Secondary outcomes: Oral gluc

  6. Slide 6: Clinical Summary

    Clinical Summary Study MSI-1436C-103 Phase 1: ASD –obese/overweight type 2 diabetic subjects – First dose administered January 17; Last patient visit June 24 – Endpoints included PK and safety in special population – Additional endpoints: short-term glucose control indices, glucose tolerance, evalua

  7. Slide 7: MSI-1436 Reduces Body Weight After a Single Dose

    MSI-1436 Reduces Body Weight After a Single Dose Phase 1 (Study 103) in Obese and Overweight Type 2 Diabetic Subjects 0.5% Weight Loss Day -1 to 3 0.0% -0.5% Placebo -1.0% 3 mg/m² 6 mg/m² -1.5% 10 mg/m² 15 mg/m² -2.0% -2.5%

  8. Slide 8: Clinical Summary

    Clinical Summary Study MSI-1436C-101 Phase 1: ASD –healthy obese subjects – First dose administered May 17; Last patient visit October 24 – Endpoints included PK and safety – 38 subjects (6 cohorts) – Single dosesof 0.3, 1, 3, 10, 20 and 40 mg/m 2 Results – Most adverse events (AEs) were transient a

  9. Slide 9: Trodusquemine and Insulin Resistance in Healthy Obese and Overweight Subjects

    Trodusquemine and Insulin Resistance in Healthy Obese and Overweight Subjects 2-3 Fold Lower Post-prandial Serum Insulin Concentrations Maintain Normal Post-prandial Serum Glucose Following Higher Doses of Trodusqueminein StudyMSI-1436C-101(a) Mean Serum Glucose Following a Single Dose of MSI- Serum

  10. Slide 10: Preclinical Summary

    Preclinical Summary • MSI-1436 is a potent insulin sensitizer – In animal models, the onset of MSI-1436’s insulin pathway actions is rapid and profound • MSI-1436 produces dramatic and durable weight loss – Weight loss is focused in the fat compartment, with no protein or bone loss • The potential v

  11. Slide 11: Preclinical Summary

    Preclinical Summary Male DIO Rats (F344); n=6 per group 45% kcal diet for 20 weeks prior to dosing (>450 grams each)

  12. Slide 12: Preclinical Summary

    Preclinical Summary MSI-1436 and Type 2 Diabetes 200 175 Improves 150 Insulin 125 Single 1436 dose at t-1 day Sensitivity 100 Vehicle Insulin bolus at t = 0 Ob/Ob mice (Independent of weight loss) Trodusquemine Fasting Blood Glucose, mg/dL 75 Pair-fed 0 30 60 90 120 Time, min. 400 Multiple 1436 dose

  13. Slide 13: Preclinical Summary

    Preclinical Summary MSI-1436 and Obesity Induced Weight Loss (DIO mouse) • Proportional to pre-treatment body weight • Weight lost is all fat* • No muscle loss * Determined by Body Composition Analysis

  14. Slide 14: MEDI-528 Phase 2 Plan

    MEDI-528 Phase 2 Plan • CP-138: Phase 2, Single Dose IV (completed) – Primary outcome: Inhibition of late asthmatic response Status: Data FPFV: Nov 2006 LPLV: Aug 2007 • CP-139: Phase 2, Single Dose IV – Primary outcome: Neutralization of IL-9 in bronchoalveolar lavage fluid Status: Ongoing FPFV: Ju

  15. Slide 15: Corporate Milestones

    Corporate Milestones Trodusquemine(MSI-1436) Expected Timing Study 103 (Phase 1 -Obese T2D, Single Ascending Dose) Initiated January 17 Keystone Symposia –preclinical data presented January 24 Study 103 (Phase 1 -Obese, T2D, Single Ascending Dose) LPI June 2008 American Diabetes Association June 6-1

  16. Slide 16: Financial Summary

    Financial Summary • Balance Sheet (06/30/08) – Cash $12.8M – Total assets (excluding cash) $821K – Total liabilities $1.75M • Cash into mid-2009 • Shares Outstanding – Common stock 17.5M – Warrants 5.2M – Options 4.2M

  17. Slide 17: For more information, contact: Jennifer Bilotti

    For more information, contact: Jennifer Bilotti Senior VP, Corporate Communications (610) 941-4004 jbilotti@genaera.com www.genaera.com NASDAQ:GENR ©2008 Genaera Corporation Inc.

Genaera — BIO Investor Forum 2008 on 6ix